WHITEHAWK THERAPEUTICS, INC.: research and development expense
Research and development expense for WHITEHAWK THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All WHITEHAWK THERAPEUTICS, INC. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 90,963,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104158 |
| 2024-01-01 | 2024-12-31 | 51,030,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104158 |
| 2023-01-01 | 2023-12-31 | 48,929,000 | USD | 2025-03-28 | 10-K · 0001628280-25-015269 |
| 2022-01-01 | 2022-12-31 | 32,662,000 | USD | 2024-03-13 | 10-K · 0001628280-24-010901 |
| 2021-01-01 | 2021-12-31 | 19,670,000 | USD | 2023-03-29 | 10-K · 0001628280-23-009583 |
| 2020-01-01 | 2020-12-31 | 15,008,000 | USD | 2022-03-17 | 10-K · 0001564590-22-010721 |
| 2019-01-01 | 2019-12-31 | 12,824,402 | USD | 2021-03-11 | 10-K · 0001564590-21-012252 |
| 2018-01-01 | 2018-12-31 | 17,852,756 | USD | 2020-03-16 | 10-K · 0001564590-20-011174 |
| 2017-01-01 | 2017-12-31 | 12,147,132 | USD | 2019-03-07 | 10-K · 0001564590-19-006602 |
| 2016-01-01 | 2016-12-31 | 11,367,590 | USD | 2018-03-15 | 10-K · 0001564590-18-005868 |
Related financial histories
- WHITEHAWK THERAPEUTICS, INC.: total assets
- WHITEHAWK THERAPEUTICS, INC.: total liabilities
- WHITEHAWK THERAPEUTICS, INC.: stockholders equity
- WHITEHAWK THERAPEUTICS, INC.: cash and cash equivalents
- WHITEHAWK THERAPEUTICS, INC.: net income or loss
- WHITEHAWK THERAPEUTICS, INC.: operating cash flow
- WHITEHAWK THERAPEUTICS, INC.: capital expenditure payments
- WHITEHAWK THERAPEUTICS, INC.: contract revenue excluding tax
- WHITEHAWK THERAPEUTICS, INC.: financing cash flow
- WHITEHAWK THERAPEUTICS, INC.: investing cash flow
- WHITEHAWK THERAPEUTICS, INC.: retained earnings or deficit
- WHITEHAWK THERAPEUTICS, INC.: basic weighted-average shares
- WHITEHAWK THERAPEUTICS, INC.: diluted weighted-average shares
- WHITEHAWK THERAPEUTICS, INC.: basic earnings per share
- WHITEHAWK THERAPEUTICS, INC.: diluted earnings per share
- WHITEHAWK THERAPEUTICS, INC.: income tax expense or benefit
- WHITEHAWK THERAPEUTICS, INC.: net property, plant and equipment
- WHITEHAWK THERAPEUTICS, INC.: share-based compensation expense
- WHITEHAWK THERAPEUTICS, INC.: operating income or loss
- WHITEHAWK THERAPEUTICS, INC.: current assets
- WHITEHAWK THERAPEUTICS, INC.: interest expense
- WHITEHAWK THERAPEUTICS, INC.: current liabilities
- WHITEHAWK THERAPEUTICS, INC.: current accounts payable
- WHITEHAWK THERAPEUTICS, INC.: net finite-lived intangible assets
- WHITEHAWK THERAPEUTICS, INC.: net current accounts receivable
- WHITEHAWK THERAPEUTICS, INC.: operating expenses
- WHITEHAWK THERAPEUTICS, INC.: net inventory
- WHITEHAWK THERAPEUTICS, INC.: selling, general and administrative expense
Inspect the source
- Entity
- WHITEHAWK THERAPEUTICS, INC. / CIK 0001422142
- Captured
- 2026-09-20T08:03:20.803Z
- SEC response SHA-256
0bc3518b433577b57088b38c087953d494e28bdd319b1da3b435ea8e7e18b0c1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001422142.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))